Back to News
Market Impact: 0.25
Corvus Begins Patient Enrollment In Phase 1b Soquelitinib Trial For Hidradenitis Suppurativa
Source: Nasdaq
Healthcare & Biotech
Corvus Pharmaceuticals initiated a Phase 1b trial of soquelitinib in patients with moderate-to-severe hidradenitis suppurativa, with enrollment now underway. The early-stage clinical milestone expands development activity for the drug, though efficacy and safety data have not yet been reported.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
CRVS0.55
More News
- One of our most recent defensive buys cleared a hurdle and its stock jumped
- Cullinan initiates FDA filing for lung cancer drug zipalertinib
- Moderna to replace Warner Bros Discovery on Nasdaq 100
- Why McKesson Stock Soared More Than 5% Higher Today
- This biotech making precision medicines for cancer could nearly triple, says JPMorgan
- The Dow's rough month, Micron's revenue surge, Google launches Gemini 4 and more in Morning Squawk